AMAG Pharma (AMAG) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Depreciation
Non-cash equity-based compensation expense	16.81M
Non-cash income tax benefit
Amortization of premium/discount on purchased securities	518K
Fair value adjustment of settlement rights
Losses (gains) on investments, net	24K
Accounts receivable, net	15.6M
Inventories	-1.37M
Receivable from collaboration	428K
Prepaid and other current assets	-1.29M
Accounts payable and accrued expenses	19.94M
Deferred revenues	21.89M
Other long-term liabilities
Total adjustments
Net cash (used in) provided by operating activities
Proceeds from sales or maturities of available-for-sale investments	71.73M
Purchases of available-for-sale investments	-142.18M
Capital expenditures
Net cash used in investing activities
Proceeds from the exercise of stock options	1.42M
Proceeds from the issuance of common stock, net of underwriting discounts and other expenses	0
Proceeds from the issuance of common stock under ESPP	760K
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of the period	228.71M
Cash and cash equivalents at end of the period	305.28M

Entities mentioned with AMAG

View All Entities